Advanced search
Publication Cover
Leukemia & Lymphoma Volume 51, 2010 - Issue 1
Submit an article Journal homepage
288
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma

Peter MoosmannCenter of Oncology, Hematology, and Transfusion Medicine, Kantonsspital Aarau, Aarau, SwitzerlandCorrespondence[email protected]
,
Marc HeizmannCenter of Oncology, Hematology, and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland
,
Nina KotrubczikCenter of Oncology, Hematology, and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland
,
Martin WernliCenter of Oncology, Hematology, and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland
&
Mario BargetziCenter of Oncology, Hematology, and Transfusion Medicine, Kantonsspital Aarau, Aarau, Switzerland
Pages 149-152 | Received 24 Apr 2009, Accepted 21 Aug 2009, Published online: 01 Oct 2009

References

  • Leoni LM, Bailey B, Reifert J, et al Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008;14:309–317.
  • Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492–1501.
  • Weide R, Pandorf A, Heymanns J, Köppler H. Bendamustine/mitoxantrone/rituximab (BMR); a very effective, well tolerated outpatient chemoimmuntherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 2004;45:2445–2449.
  • Königsmann M, Knauf W, Herold M, et al Fludarabine and bendamustine in refractory and relapsed indolent lymphoma – a multicenter phase I/II trial of the East German Society of Hematology and Oncology (OSHO). Leuk Lymphoma 2004;45:1821–1827.
  • Rummel MJ, Al-Batran SE, Kim SZ, et al Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383–3389.
  • Robinson KS, Williams ME, van der Jagt RH, et al Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473–4479.
  • Belch A, Kouroukis CT, Crump M, et al A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007;18:116–121.
  • Fisher RI, Bernstein SH, Kahl BS, et al Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867–4874.
  • Kane RC, Dagher R, Farrell A, et al Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007;13:5291–5294.
  • Schöffski P, Hagedorn T, Grunwald V, et al Weekly administration of bendamustine: a phase I study in patients with advanced solid tumours. Ann Oncol 2000;11:729–734.
  • Papandreou CN, Daliani DD, Nix D, et al Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2005;22:2108–2121.
  • Attar EC, Learner E, Amrein PC. In vitro studies of bortezomib with daunorubicin and cytarabine: sequence of administration affects leukemia cell chemosensitivity. ASH Annual Meeting Abstracts 2004;104:4464.
  • Hainsworth JD, Spigel DR, Barton J, et al Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008;113:765–771.
  • Matous J, Letzer J, Rosen P, et al Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: dose finding results of the VERTICAL study. J Clin Oncol 2009;27Suppl:15s. Abstract 8550

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.